Next Article in Journal
Optimization of Cold Chain Logistics with Fuzzy MCDM Model
Previous Article in Journal
Automation of Modeling and Calibration of Integrated Preparative Protein Chromatography Systems
Previous Article in Special Issue
Production of Bivalent Subunit Vaccine for Porcine via 2A-Like Sequence in Baculovirus Expression Vector System
Review

Recombinant Protein Technology in the Challenging Era of Coronaviruses

1
Biochemistry and Biotechnology Group, Department of Chemistry, College of Science, Chung Yuan Christian University, Chungli District, Taoyuan City 320, Taiwan
2
Genetic Engineering Laboratory, Department of Bioscience Technology, College of Science, Chung Yuan Christian University, Chungli District, Taoyuan City 320, Taiwan
*
Author to whom correspondence should be addressed.
Academic Editor: Carla Silva
Processes 2022, 10(5), 946; https://doi.org/10.3390/pr10050946
Received: 31 March 2022 / Revised: 4 May 2022 / Accepted: 8 May 2022 / Published: 10 May 2022
(This article belongs to the Special Issue State of the Art of Protein Expression Systems)
Coronaviruses have caused devastation in both human and animal populations, affecting both health and the economy. Amidst the emergence and re-emergence of coronaviruses, humans need to surmount the health and economic threat of coronaviruses through science and evidence-based approaches. One of these approaches is through biotechnology, particularly the heterologous production of biopharmaceutical proteins. This review article briefly describes the genome, general virion morphology, and key structural proteins of different coronaviruses affecting animals and humans. In addition, this review paper also presents the different systems in recombinant protein technology such as bacteria, yeasts, plants, mammalian cells, and insect/insect cells systems used to express key structural proteins in the development of countermeasures such as diagnostics, prophylaxis, and therapeutics in the challenging era of coronaviruses. View Full-Text
Keywords: coronavirus; recombinant protein; heterologous host; protein expression systems; diagnostics; vaccines; therapeutics coronavirus; recombinant protein; heterologous host; protein expression systems; diagnostics; vaccines; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Cabal, A.B.S.; Wu, T.-Y. Recombinant Protein Technology in the Challenging Era of Coronaviruses. Processes 2022, 10, 946. https://doi.org/10.3390/pr10050946

AMA Style

Cabal ABS, Wu T-Y. Recombinant Protein Technology in the Challenging Era of Coronaviruses. Processes. 2022; 10(5):946. https://doi.org/10.3390/pr10050946

Chicago/Turabian Style

Cabal, Ace B.S., and Tzong-Yuan Wu. 2022. "Recombinant Protein Technology in the Challenging Era of Coronaviruses" Processes 10, no. 5: 946. https://doi.org/10.3390/pr10050946

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop